Adherex Technologies (NASDAQ:FENC – Get Free Report) and Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
Profitability
This table compares Adherex Technologies and Contineum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adherex Technologies | -6.09% | -5.71% | -2.37% |
| Contineum Therapeutics | N/A | -24.73% | -23.51% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Adherex Technologies and Contineum Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adherex Technologies | 1 | 1 | 4 | 0 | 2.50 |
| Contineum Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
Volatility & Risk
Adherex Technologies has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Earnings & Valuation
This table compares Adherex Technologies and Contineum Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adherex Technologies | $59.22 million | 6.35 | -$9.74 million | ($0.13) | -82.38 |
| Contineum Therapeutics | N/A | N/A | -$59.98 million | ($1.73) | -7.73 |
Adherex Technologies has higher revenue and earnings than Contineum Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
55.5% of Adherex Technologies shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Adherex Technologies beats Contineum Therapeutics on 8 of the 11 factors compared between the two stocks.
About Adherex Technologies
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
